Valuation: Thalia Therapeutics Plc

Market Cap 4.37M 5.84M 5.1M 4.69M 8.28M 556M 8.42M 56.41M 21.86M 273M 21.93M 21.45M 940M P/E 2023
-1.63x
P/E 2024 -1.69x
Enterprise Value 3.74M 5M 4.37M 4.01M 7.1M 476M 7.22M 48.33M 18.73M 234M 18.78M 18.38M 805M EV / Sales 2023
643,891,449x
EV / Sales 2024 198,657,512x
Free-Float
42.82%
Yield 2023 *
-
Yield 2024 -

Last Transcript: Thalia Therapeutics Plc

3 months+44.44%
6 months+23.81%
Current year+23.81%
1 week 0.6
Extreme 0.6
0.7
1 month 0.55
Extreme 0.55
0.7
Current year 0.4
Extreme 0.4
0.95
1 year 0.35
Extreme 0.35
1
3 years 0.35
Extreme 0.35
2.1
5 years 0.35
Extreme 0.35
10.43
10 years 0.35
Extreme 0.35
35.7
Manager TitleAgeSince
Chief Executive Officer 66 2026-02-23
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer 56 2025-05-26
Director TitleAgeSince
Director/Board Member 48 2020-07-13
Chairman 59 2023-07-31
Director/Board Member 81 2024-09-08
Date Insider Type Main position Quantity % Market Cap.
24-11-27Free

Chairman

3,000,000 0.7599%
24-11-27Free

Director

3,000,000 0.7599%
24-11-27Free

Founder

6,000,000 1.5198%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+73.33%-59.38% 7.18M
+3.98%+5.55%+76.40%+136.18% 56.21B
-3.12%+5.11%+71.57%+94.67% 55.38B
+2.92%+7.49%-10.64%-10.28% 23.75B
+2.16%+4.43%+11.05%+425.78% 23.19B
+3.64%+10.54%+39.81%-4.50% 18.14B
+4.11%+8.89%+44.60%-27.73% 16.84B
+2.57%+20.26%+181.98%+355.99% 15.86B
+1.58%+3.21%+24.02%+187.19% 13.56B
+7.20%+10.70%+42.91% - 12.97B
Average +2.52%+6.15%+55.50%+121.99% 23.59B
Weighted average by Cap. +1.96%+6.09%+57.24%+135.30%

Financials

2023 2024
Net sales 0 0 0 0 0 0.25 0 0.03 0.01 0.12 0.01 0.01 0.42 0.01 0.01 0.01 0.01 0.01 0.93 0.01 0.09 0.04 0.45 0.04 0.04 1.57
Net income -1.27M -1.7M -1.48M -1.36M -2.41M -161M -2.45M -16.39M -6.35M -79.21M -6.37M -6.23M -273M -1.06M -1.41M -1.24M -1.14M -2.01M -135M -2.04M -13.67M -5.3M -66.06M -5.31M -5.2M -228M
Net Debt -1.03M -1.37M -1.2M -1.1M -1.95M -131M -1.98M -13.26M -5.14M -64.09M -5.15M -5.04M -221M -626K -837K -731K -671K -1.19M -79.64M -1.21M -8.08M -3.13M -39.06M -3.14M -3.07M -135M
Logo Thalia Therapeutics Plc
Thalia Therapeutics PLC, formerly N4 Pharma plc, is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. The Company is developing proprietary RNA delivery technologies (Nuvec) designed to enable multi-RNA loading, flexible targeting and the potential for oral delivery. Nuvec is based on amorphous silica and has an irregular surface structure that simply and effectively traps and protects RNA as it travels to target cells. The Nuvec delivery system can be functionalized by attaching a wide range of proteins, peptides, antibodies or radionuclides for therapeutic purposes. The Company has a growing pipeline of RNA-based programs across oncology and cardiovascular disease, including Dual-target cardiovascular siRNA program and Proprietary RNA delivery technology. The Company is advancing a novel long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein.
Employees
3
Date Price Change Volume
26-07-02 GBX 0.6500 0.00% 100,000
26-07-01 GBX 0.6500 0.00% 9,735,131
26-06-30 GBX 0.6500 0.00% 215,510
26-06-29 GBX 0.6500 0.00% 40,854
26-06-26 GBX 0.6500 0.00% 3,354,651
  1. Stock Market
  2. Stocks
  3. THAT Stock